Treating with Duvyzat®
Adverse event reporting information can be found at the bottom of this page.
Click HERE for prescribing information.
Treatment with Duvyzat® should be initiated by a physician experienced in the management of Duchenne muscular dystrophy
Duvyzat® is a convenient oral formulation for patients
- Duvyzat® is a liquid suspension for oral use, administered with the provided graduated oral syringe
- The recommended dosage of Duvyzat® is based on body weight and administered twice daily with food
- Prior to starting treatment on Duvyzat®, obtain the required baseline assessments
Real patient currently on Duvyzat® treatment. Photograph for illustrative purposes only, individual results may vary
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to ITF Pharma Ltd Medical Information on: 0800 098 4040 or UK.Medical.Information@italfarmacogroup.com
Product Quality Complaints should also be reported to ITF Pharma Ltd Medical Information on: 0800 098 4040 or UK.Medical.Information@italfarmacogroup.com
References
- Duvyzat Summary of Product Characteristics, MHRA, https://www.medicines.org.uk/emc/product/100605/smpc
